PP_1170x120_10-25-21

Zeposia (ozanimod) 0.92 mg

FDA approves Bristol Myers Squibb’s Zeposia

FDA approves Bristol Myers Squibb’s Zeposia

PRINCETON, N.J. — Bristol-Myers Squibb Co. announced Thursday that the U.S. Food and Drug Administration (FDA) approved Zeposia (ozanimod) 0.92 mg for the treatment of adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.  Zeposia, an oral medication taken once daily, is the only approved

Adheris Health